I would think they are training more doctors in how to best utilize the App so when they do press the go button then maybe 40% (80 doctors) will be fully conversant with how to use dx. They don't require more than 40% of their available doctors to be (initially anyway) very conversant with ResApdx diagnosis as that is the top end of their telehealth enquiries...around 30% to 40% are respiratory calls. Therefore 30% to 40% of their own doctors are all that should require the detailed training with ResApdx.
So as long as they have that percentage of doctors on each shift they will be able to service their calls amazingly well. The rest of their doctors I would imagine would be brought up to speed with ResApdx as time progresses.
They would have started with maybe a half dozen of their doctors for the trial...now they are seeing the all round benefits they are taking the bull by the horns and training up many more of their doctors. Great result...and expected when you think about it...the news is early as well so how positive is that?
- Forums
- ASX - By Stock
- Ann: Medgate extends European ResAppDx trial
I would think they are training more doctors in how to best...
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online